Numerous studies, including large clinical trials, have demonstrated the greater value of tissue ACE inhibition vs. serum ACE inhibition in patients with hypertension, diabetes, renal disease, and heart failure [144]. The gene discussed is ACE; the disease is hypertensive disorder.